Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - apomorfino hidrochloridas - injekcinis ar infuzinis tirpalas - 10 mg/ml - apomorphine

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - ibuprofenas - plėvele dengtos tabletės - 200 mg - ibuprofen

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - letrozolas - plėvele dengtos tabletės - 2,5 mg - letrozole

European Union - Lithuanian - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatide - osteoporozė - kalcio homeostazė - movymia vartojamas suaugusiesiems. osteoporozės po menopauzės moterims, ir vyrams, kuriems padidėjusi kaulų lūžių rizika. moterims po menopauzės stuburo ir ne stuburo slankstelių lūžių, bet ne šlaunikaulio, lūžių dažnis reikšmingai sumažėjo akivaizdžiai. gydymo osteoporozės susijusi su ilgalaikis sisteminis gliukokortikoidų terapija moterims ir vyrams padidėjusi rizika lūžis.

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - alprazolamas - tabletės - 0,5 mg; 0,25 mg; 1 mg - alprazolam

European Union - Lithuanian - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - mirtazapinas - plėvele dengtos tabletės - 30 mg; 15 mg - mirtazapine

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - o-(beta-hidroksietil)-rutozidai - šnypščiosios tabletės - 1000 mg; 20 mg/g; 500 mg - rutoside

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - ibuprofenas/fenilefrino hidrochloridas - plėvele dengtos tabletės - 400 mg/10 mg - ibuprofen, combinations

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

niromed, uab - kvinaprilis/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/12,5 mg - quinapril and diuretics